Vectibix market seen rising to $2 million by 2030
The Business Research Company says the global market for Vectibix (panitumumab) is projected to grow from $1.48 million in 2026 to $2 million by 2030, driven by rising colorectal cancer cases and wider use of precision oncology. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.
Why it matters: - Vectibix (panitumumab) is tied to treatment demand in metastatic colorectal cancer, a disease area with rising case counts. - The forecast points to sustained growth in targeted cancer therapies, precision medicine, and biomarker-driven care. - The report signals where oncology spending and adoption may concentrate over the next several years.
What happened: - The Business Research Company released its Vectibix (panitumumab) Global Market Report 2026, covering market size, trends, and forecasts through 2035. - The report estimates the Vectibix market rose from $1.37 million in 2025 to $1.48 million in 2026. - The report projects the market will reach $2 million by 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period.
The details: - The report pegs 2025-2026 growth at 8.0% CAGR and 2026-2030 growth at 7.7% CAGR. - Historic growth was linked to regulatory approvals for metastatic colorectal cancer, EGFR inhibition, oncology specialist adoption, higher colorectal cancer incidence, and advances in targeted therapies. - Future growth is expected to come from greater use of precision medicine, better cancer diagnostics, expansion into other cancer indications, higher oncology healthcare spending, and improved patient stratification. - Key trends identified in the report include more reliance on EGFR-targeted therapies, broader precision oncology use, biomarker-driven patient selection, hospital adoption of monoclonal antibodies, and combination therapies for advanced cancer. - Vectibix is a monoclonal antibody used in cancer therapy, especially for patients with metastatic colorectal cancer. - Panitumumab targets EGFR, a protein on certain cancer cells. - By binding to EGFR, the drug blocks activation by natural growth factors and disrupts signaling tied to cell division and tumor growth. - The report says the mechanism helps slow cancer progression in suitable patients. - The growing incidence of colorectal cancer is a major demand driver. - In February 2025, the American Cancer Society estimated 154,270 new colorectal cancer cases in the United States, up from 152,810 in 2024. - The report also ties demand to the move toward personalized medicine, which uses genetic and health profiles to guide treatment. - In February 2024, the Personalized Medicine Coalition said the U.S. FDA approved 26 new personalized medicines in 2023, up from 12 in 2022. - The report includes coverage of Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company also says the 2026 report series includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offers a free sample and a full version online: the market report sample and the full market report.
Between the lines: - The forecast implies Vectibix’s growth will depend less on broad oncology uptake and more on tighter patient selection. - The market outlook reflects a shift toward therapies that fit genetic testing and precision oncology workflows. - Regional growth differences suggest mature demand in North America and faster adoption potential in markets expanding cancer care access.
What's next: - The market is expected to keep growing as precision medicine expands and more patients are stratified by biomarkers. - Adoption could widen if Vectibix is used in additional cancer indications or in more combination regimens. - Asia-Pacific may narrow the gap with North America if cancer screening, diagnosis, and oncology access continue to improve.
The bottom line: - Vectibix remains a niche oncology drug, but the market outlook points to steady long-term growth as targeted cancer treatment becomes more common.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Middle East Culture Guide
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.